Energy balance
GLP-1 receptor agonists and GIP analogs show potential for achieving Type 2 diabetes remission through significant weight loss, but current trial data is limited.
For those with overweight or obesity, GLP-1 and GIP-based medications can facilitate significant weight loss, which is a key driver for Type 2 diabetes remission. While trials are still mapping their long-term efficacy for remission, they represent a promising tool for achieving weight loss goals necessary for reversing the disease.
Future trials should focus on using GLP-1 receptor agonists and GIP analogs, and their role in weight loss and T2D. ... individuals may achieve remission with ≥ 10% or ≥ 10 kg weight loss which is a feasible goal with the use of GLP-1 receptor agonists and GIP analogs in patients living with overweight or obesity
Why this rating
Based on the mapping of registered trials showing very few recent trials using these agents, despite their clinical popularity.
Source
Registered clinical trials targeting type 2 diabetes remission with pharmacological interventions
Nicholas Shoung et al. · Scientific Reports · 2025
DOI 10.1038/s41598-025-00080-9
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →